About: The use of oral recombinant feline interferon omega in two cats with type II diabetes mellitus and concurrent feline chronic gingivostomatitis syndrome

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The use of oral recombinant feline interferon omega in two cats with type II diabetes mellitus and concurrent feline chronic gingivostomatitis syndrome Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The use of oral recombinant feline interferon omega in two cats with type II diabetes mellitus and concurrent feline chronic gingivostomatitis syndrome
Creator	Gil, Solange Tavares, Luís Leal, Rodolfo Mcgahie, David Brito, Maria Niza, Maria
Source	Medline; PMC
abstract	Feline Chronic Gingivostomatitis Syndrome (FCGS) is a common disease in clinical practice. Among the therapeutic options available, long-acting corticosteroids are frequently used due to their anti-inflammatory and immunosuppressive properties. Although they may improve the clinical symptoms, they can lead to a progressive form of the disease that becomes refractory to treatment. Furthermore, their direct relationship with type II diabetes mellitus (DM) is well known. Consequently, these drugs are controversial and not recommended for routine management of FCGS. Recombinant feline interferon-omega (rFeIFN-ω) is an immunomodulatory compound. Recently, its daily oral administration has been shown to be successful in treating refractory cases of FCGS. This case study describes two clinical cases of type II DM complicated by FCGS. Both animals were calicivirus positive and they had been previously treated with long-acting corticosteroids, which may have been the major cause of DM. The two cats were treated with glargine insulin (Lantus, starting dose 1 IU/cat twice daily (BID)), achieving remission 10 and 18 weeks later respectively. Considering the difficulty with control of FCGS in these animals, an oral daily dose of rFeIFN-ω was started as an alternative to long-acting corticosteroids. In both cats oral clinical signs gradually improved and 60 days after the start of therapy the owners reported a significant relief of pain during mastication. According to the authors’ knowledge, this is the first case report that describes the successful use of rFeIFN-ω in the management of FCGS in type II diabetic cats, in which long-acting corticosteroids are contraindicated.
has issue date	2013-10-23(xsd:dateTime)
bibo:doi	10.1186/2046-0481-66-19
bibo:pmid	24153100
has license	cc-by
sha1sum (hex)	25742d7fc7e3a5dfd8af95c2dbc9731494d13e67
schema:url	https://doi.org/10.1186/2046-0481-66-19
resource representing a document's title	The use of oral recombinant feline interferon omega in two cats with type II diabetes mellitus and concurrent feline chronic gingivostomatitis syndrome
has PubMed Central identifier	PMC3816157
has PubMed identifier	24153100
schema:publication	Ir Vet J
resource representing a document's body	covid:25742d7fc7e3a5dfd8af95c2dbc9731494d13e67#body_text
is schema:about of	named entity 'FELINE' named entity 'CONCURRENT' named entity 'CHRONIC' named entity 'management' named entity 'authors' named entity 'feline' named entity 'treating' named entity 'daily' named entity 'interferon' named entity 'oral' covid:arg/25742d7fc7e3a5dfd8af95c2dbc9731494d13e67 named entity 'WITH TYPE' named entity 'MAJOR' named entity 'DIRECT' named entity 'RELATIONSHIP' named entity 'ORAL ADMINISTRATION' named entity 'CATS' named entity 'TYPE II' named entity 'SIGNIFICANT' named entity 'KNOWLEDGE' named entity 'COMPLICATED BY' named entity 'REPORTED' named entity 'DOSE' named entity 'RELIEF' named entity 'FELINE' named entity 'CONTRAINDICATED' named entity 'THESE' named entity 'RECENTLY' named entity 'OWNERS' named entity 'DRUGS' named entity 'II DM' named entity 'COMMON DISEASE' named entity 'A COMMON' named entity 'CLINICAL SYMPTOMS' named entity 'STARTED' named entity 'USE OF' named entity 'DAYS' named entity 'MANAGEMENT' named entity 'REMISSION' named entity 'CONSIDERING' named entity 'RECOMBINANT' named entity 'CAUSE' named entity 'CORTICOSTEROIDS' named entity 'CASE REPORT' named entity 'DIFFICULTY WITH' named entity 'THEIR' named entity 'CHRONIC' named entity 'TWICE DAILY' named entity 'ANIMALS' named entity 'USED' named entity 'TREATED WITH' named entity 'PREVIOUSLY TREATED' named entity 'CATS' named entity 'GINGIVOSTOMATITIS' named entity 'THERAPEUTIC' named entity 'REFRACTORY' named entity 'DAILY' named entity 'GLARGINE INSULIN' named entity 'ACCORDING' named entity 'INTERFERON' named entity 'FREQUENTLY' named entity 'SYNDROME' named entity 'LATER' named entity '18 WEEKS' named entity 'ORAL' named entity 'WITH TYPE' named entity 'ITS' named entity 'MAY HAVE' named entity 'CASES' named entity 'INTERFERON OMEGA' named entity 'TYPE II DIABETES MELLITUS' named entity 'SYNDROME' named entity 'RECOMBINANT' named entity 'SUCCESSFUL' named entity 'TREATING' named entity 'ALTERNATIVE'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software